These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11994118)

  • 41. Somatostatin analogues for treatment of polycystic liver disease.
    Gevers TJ; Drenth JP
    Curr Opin Gastroenterol; 2011 May; 27(3):294-300. PubMed ID: 21191289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The potential role of somatostatin analogues in breast cancer treatment.
    Pollak M
    Yale J Biol Med; 1997; 70(5-6):535-9. PubMed ID: 9825480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
    Weber M
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):12-7. PubMed ID: 25768104
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
    Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
    Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long?
    Jacob JJ; Bevan JS
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):812-7. PubMed ID: 25039940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.
    Strasburger CJ; Karavitaki N; Störmann S; Trainer PJ; Kreitschmann-Andermahr I; Droste M; Korbonits M; Feldmann B; Zopf K; Sanderson VF; Schwicker D; Gelbaum D; Haviv A; Bidlingmaier M; Biermasz NR
    Eur J Endocrinol; 2016 Mar; 174(3):355-62. PubMed ID: 26744896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
    Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
    Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Somatostatin receptor status in non-medullary thyroid carcinoma].
    Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
    Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
    Grozinsky-Glasberg S; Grossman AB; Korbonits M
    Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours.
    Shah T; Caplin M
    Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):617-36. PubMed ID: 16183531
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
    Janson ET; Oberg K
    Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
    [No Abstract]   [Full Text] [Related]  

  • 55. Somatostatin analogues in the treatment of thyroid eye disease.
    Krassas GE
    Thyroid; 1998 May; 8(5):443-5. PubMed ID: 9623741
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors].
    Xu JM
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):158-60. PubMed ID: 22780939
    [No Abstract]   [Full Text] [Related]  

  • 57. A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
    Turner HE; Vadivale A; Keenan J; Wass JA
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):275-80. PubMed ID: 10469005
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.
    Cano JM; Galán R; López R
    Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates.
    Khagi S; Saif MW
    JOP; 2014 Mar; 15(2):135-7. PubMed ID: 24618437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Medical treatment of pituitary adenoma].
    Chanson P
    Rev Prat; 1996 Jun; 46(12):1509-13. PubMed ID: 8881166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.